Ameriprise
UTHR icon

Ameriprise’s United Therapeutics UTHR Stock Holding History

Ameriprise’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$54.1M Sell
91,225
-9,817
-10% -$4.89M 0.01% 834
2025
Q4 		$49.2M Buy
101,042
+37,661
+59% +$17.5M 0.01% 888
2025
Q3 		$26.6M Buy
63,381
+3,660
+6% +$1.23M 0.01% 1211
2025
Q2 		$17.2M Sell
59,721
-6,509
-10% -$1.95M ﹤0.01% 1446
2025
Q1 		$20.4M Sell
66,230
-658
-1% -$225K 0.01% 1299
2024
Q4 		$23.6M Buy
66,888
+19
+0% +$6.98K 0.01% 1228
2024
Q3 		$24M Sell
66,869
-6,428
-9% -$2.17M 0.01% 1222
2024
Q2 		$23.4M Buy
73,297
+2,301
+3% +$609K 0.01% 1182
2024
Q1 		$16.3M Sell
70,996
-2,037
-3% -$460K ﹤0.01% 1434
2023
Q4 		$16.1M Sell
73,033
-6,406
-8% -$1.48M ﹤0.01% 1409
2023
Q3 		$17.9M Sell
79,439
-978
-1% -$225K 0.01% 1296
2023
Q2 		$17.8M Sell
80,417
-6,453
-7% -$1.43M 0.01% 1344
2023
Q1 		$19.5M Buy
86,870
+7,359
+9% +$1.81M 0.01% 1281
2022
Q4 		$22.1M Sell
79,511
-2,786
-3% -$703K 0.01% 1178
2022
Q3 		$17.2M Buy
82,297
+1,540
+2% +$344K 0.01% 1276
2022
Q2 		$19M Sell
80,757
-1,757
-2% -$357K 0.01% 1238
2022
Q1 		$14.8M Sell
82,514
-1,034
-1% -$197K ﹤0.01% 1587
2021
Q4 		$18.1M Buy
83,548
+2,151
+3% +$422K 0.01% 1502
2021
Q3 		$15M Sell
81,397
-2,418
-3% -$476K ﹤0.01% 1501
2021
Q2 		$15M Sell
83,815
-72,266
-46% -$13.8M ﹤0.01% 1573
2021
Q1 		$26.1M Sell
156,081
-23,828
-13% -$3.97M 0.01% 1124
2020
Q4 		$27.3M Sell
179,909
-21,544
-11% -$2.83M 0.01% 1044
2020
Q3 		$20.3M Buy
201,453
+6,334
+3% +$695K 0.01% 1062
2020
Q2 		$23.6M Buy
195,119
+15,424
+9% +$1.74M 0.01% 969
2020
Q1 		$17M Buy
179,695
+56,200
+46% +$5.34M 0.01% 1035
2019
Q4 		$10.9M Sell
123,495
-7,326
-6% -$645K ﹤0.01% 1680
2019
Q3 		$10.4M Buy
130,821
+15,668
+14% +$1.26M ﹤0.01% 1658
2019
Q2 		$8.99M Sell
115,153
-6,975
-6% -$652K ﹤0.01% 1817
2019
Q1 		$14.3M Sell
122,128
-3,261
-3% -$380K 0.01% 1388
2018
Q4 		$13.7M Sell
125,389
-8,673
-6% -$1.01M 0.01% 1339
2018
Q3 		$17.1M Buy
134,062
+1,581
+1% +$196K 0.01% 1423
2018
Q2 		$15M Buy
132,481
+3,303
+3% +$363K 0.01% 1398
2018
Q1 		$14.5M Sell
129,178
-40,195
-24% -$5.11M 0.01% 1357
2017
Q4 		$25.1M Buy
169,373
+2,263
+1% +$288K 0.01% 938
2017
Q3 		$19.6M Sell
167,110
-5,936
-3% -$758K 0.01% 1051
2017
Q2 		$22.4M Buy
173,046
+27,304
+19% +$3.41M 0.01% 951
2017
Q1 		$19.7M Sell
145,742
-9,220
-6% -$1.4M 0.01% 1024
2016
Q4 		$22.2M Buy
154,962
+37,341
+32% +$4.77M 0.01% 932
2016
Q3 		$13.9M Buy
117,621
+2,265
+2% +$272K 0.01% 1191
2016
Q2 		$12.2M Buy
115,356
+1,995
+2% +$223K 0.01% 1248
2016
Q1 		$12.6M Sell
113,361
-2,642
-2% -$334K 0.01% 1243
2015
Q4 		$18.2M Sell
116,003
-667
-0.6% -$97.1K 0.01% 976
2015
Q3 		$15.3M Sell
116,670
-3,175
-3% -$509K 0.01% 1122
2015
Q2 		$20.9M Sell
119,845
-74,487
-38% -$13.4M 0.01% 981
2015
Q1 		$33.5M Buy
194,332
+18,001
+10% +$2.74M 0.02% 705
2014
Q4 		$22.8M Buy
176,331
+58,808
+50% +$7.58M 0.01% 886
2014
Q3 		$15.1M Buy
117,523
+8,615
+8% +$888K 0.01% 1140
2014
Q2 		$9.64M Sell
108,908
-4,959
-4% -$477K 0.01% 1570
2014
Q1 		$10.7M Sell
113,867
-136,524
-55% -$14M 0.01% 1450
2013
Q4 		$28.3M Sell
250,391
-12,332
-5% -$1.11M 0.02% 793
2013
Q3 		$20.7M Buy
262,723
+163,336
+164% +$11.9M 0.01% 971
2013
Q2 		$6.54M Buy
+99,387
New +$6.4M ﹤0.01% 1719

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Ameriprise's UTHR Position: Q1 2026 in Review

Ameriprise reduced its United Therapeutics (UTHR) stake by 9.7% in Q1 2026, selling an estimated $4.89M and leaving 91,225 shares worth $54.1M. The position accounts for 0.01% of the portfolio, ranked #834.

Ameriprise first reported a position in UTHR in Q2 2013 and has held it in 52 quarters since. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Ameriprise held 91,225 shares of United Therapeutics worth $54.1M as of Q1 2026.
  • Ameriprise sold 9,817 United Therapeutics shares in Q1 2026, an estimated $4.89M.
  • United Therapeutics made up 0.01% of Ameriprise's portfolio in Q1 2026, its #834 holding.
  • Ameriprise first reported a position in United Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • 850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.